Read SURMOUNT‑1 for follow-up duration and the control group
This 2022 Phase 3 trial compared tirzepatide with placebo in adults with overweight or obesity without diabetes and reported weight outcomes at 72 weeks.
What to check after reading
Record the control group, endpoint, follow-up duration, and how the outcomes were summarized.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.